Armistice Capital LLC Boosts Stock Holdings in BridgeBio Oncology Therapeutics, Inc $BBOT

Armistice Capital LLC boosted its stake in BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) by 142.7% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,000,000 shares of the company’s stock after purchasing an additional 588,000 shares during the quarter. Armistice Capital LLC’s holdings in BridgeBio Oncology Therapeutics were worth $12,520,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BBOT. CIBC Private Wealth Group LLC bought a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter worth about $63,000. Persistent Asset Partners Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics in the fourth quarter worth about $107,000. Squarepoint Ops LLC bought a new position in BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $144,000. BIT Capital GmbH purchased a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $313,000. Finally, The Manufacturers Life Insurance Company purchased a new position in BridgeBio Oncology Therapeutics during the 4th quarter valued at approximately $670,000. Institutional investors own 54.89% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on BBOT shares. Wall Street Zen cut BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $23.00 target price for the company. Finally, HC Wainwright boosted their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, March 6th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, BridgeBio Oncology Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $25.00.

BridgeBio Oncology Therapeutics Stock Performance

Shares of BBOT stock opened at $7.68 on Thursday. The stock has a market capitalization of $615.24 million, a P/E ratio of -3.75 and a beta of 0.29. BridgeBio Oncology Therapeutics, Inc has a 1 year low of $7.00 and a 1 year high of $14.87. The company’s 50 day moving average is $8.43.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last announced its earnings results on Tuesday, May 12th. The company reported ($526.11) EPS for the quarter. Equities research analysts expect that BridgeBio Oncology Therapeutics, Inc will post -2.32 earnings per share for the current fiscal year.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.